Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy

NCT ID: NCT00343759

Last Updated: 2015-12-11

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-06-30
• Study Completion Date: 2009-12-31

Brief Summary

The purpose of this study is to see what kinds of breast tumors will respond to lapatinib. Lapatinib is an experimental medicine which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

Breast Cancer

Keywords

Breast cancer; Tyrosine kinase inhibitors; Lapatinib; Biologic response modifiers; Magnetic resonance imaging; Treatment-naive, operable

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Lapatinib

Patients will take 14 days of Lapatinib prior to definitive surgery.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Histologically or cytologically-confirmed by either core or fine needle biopsy primary invasive carcinoma of the breast;
• AJCC T2-T3 disease (>2.0 cm without chest wall or skin invasion) by at least one imaging modality (either mammogram, ultrasound, or MRI) - entry criteria is based on radiologic staging and not final pathologic staging;
• ECOG performance status 0-1 (Karnofsky ≥ 70%
• Any lymph node status, hormone receptor status, and level of erbB2 expression
• No prior chemotherapy, hormonal therapy or radiation therapy to the affected breast for current or previous malignancy;
• Cardiac ejection fraction >50% or within the institutional range of normal;
• Patients must have normal organ and marrow function defined as: Leukocyte count >3000/uL; Absolute neutrophil count (ANC) ≥ 1,500/mm3, platelets > 100,000/mm3, and hemoglobin ≥ 8 gm/dl; Serum creatinine ≤ 1.5 times ULN, or 24-hour creatinine clearance ≥ 75 cc/min; Serum bilirubin ≤ 1.5 times ULN; SGOT ≤ 2.5 times ULN; alkaline phosphatase ≤ 2.5 ULN times ULN.
• The effects of lapatinib on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
• Ability to understand and the willingness to sign written informed consent document.

Exclusion Criteria

• AJCC T1, T4, or stage 4 disease;
• Patients may not have undergone incisional or excisional biopsy of their tumor;
• Patients may not be receiving any other investigational agents;
• Absolute contraindication to MRI imaging (cardiac pacemaker or any non-removable metallic foreign object in the body);
• On chronic therapy with any known inducer or inhibitor of CYP3A4
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant or lactating women are excluded from this study because lapatinib is a tyrosine kinase inhibitor with the potential for teratogenic or abortifacient effects.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

University of Pennsylvania

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Angela DeMichele, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania

Locations

Abramson Cancer Center of University of Pennsylvania

Philadelphia, Pennsylvania, United States

Countries

United States

Other Identifiers

UPCC 12104

Identifier Type: -

Identifier Source: secondary_id

803893

Identifier Type: -

Identifier Source: org_study_id